content: <PAGE>  1
                        SECURITIES AND EXCHANGE COMMISSION
  
                             Washington, D.C.  20549
  
  
  
                                     Form 8-K
  
  
  
                                  CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                                September 13, 2000
                 -------------------------------------------------
                 (Date of Report: Date of earliest event reported)
  
  
                           IMMUNOTECHNOLOGY CORPORATION
              ------------------------------------------------------
        (Exact name of registrant as specified in its charter)
  
  
           DELAWARE                    0-24641             84-1016435
  ---------------------------- -----------------------  --------------------
  (State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
   of incorporation)
  
  
  
                     1661 Lakeview Circle, Ogden, Utah  84403
                  ------------------------------------------------
                      (Address of principal executive office)
  
  
  
  Registrant's telephone number, including area code: (801) 399-3632
                                                      --------------
  
                                Not Applicable
       ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  
  
                      
  <PAGE>
  <PAGE> 2
                                ITEM 5. OTHER EVENTS
  
  
  Termination of Negotiations to Acquire Beverly Hills Auctioneers, Inc.
  ----------------------------------------------------------------------
  On May 19, 2000, the Registrant executed a letter of intent to acquire 100% of
  the outstanding common stock of Beverly Hills Auctioneers, Inc., Beverly
  Hills, California, for newly-issued shares of capital stock of the Registrant.
  The acquisition was subject to the negotiation and completion of a definitive
  agreement setting forth the terms of the acquisition. On September 13, 2000,
  the Registrant announced that negotiations on the definitive agreement and
  broken down and no agreement had been reached between the parties.
  
  (c)  Exhibits.  The following exhibits are included as part of this report:
  
              SEC
  Exhibit     Reference
  Number      Number      Title of Document                        Location
  -------     ---------   -----------------                        --------
  20.03         20        Press Release re: Termination of
                          Letter of Intent                          This Filing
  
  
                              SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the Registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunder duly authorized.
  
                                           IMMUNOTECHNOLOGY CORPORATION
  
  Date: September 25, 2000                 /S/David Knudson, Secretary/Treasurer
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "f8k00s13.txt", "description": "CURRENT REPORT ON FORM 8-K", "secsgml_size_bytes": 2972}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOTECHNOLOGY CORP", "cik": "0000789097", "assigned-sic": "6770", "irs-number": "841016435", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-24641", "film-number": "727939"}, "business-address": {"street1": "1661 LAKEVIEW CIRCLE", "city": "OGDEN", "state": "UT", "zip": "84403", "phone": "8013993632"}}
text: 1
                        SECURITIES AND EXCHANGE COMMISSION
  
                             Washington, D.C.  20549
  
                                     Form 8-K
  
                                  CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
                                September 13, 2000
                 -------------------------------------------------
                 (Date of Report: Date of earliest event reported)
  
                           IMMUNOTECHNOLOGY CORPORATION
              ------------------------------------------------------
        (Exact name of registrant as specified in its charter)
  
           DELAWARE                    0-24641             84-1016435
  ---------------------------- -----------------------  --------------------
  (State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
   of incorporation)
  
                     1661 Lakeview Circle, Ogden, Utah  84403
                  ------------------------------------------------
                      (Address of principal executive office)
  
  Registrant's telephone number, including area code: (801) 399-3632
                                                      --------------
  
                                Not Applicable
       ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)
  2
                                ITEM 5. OTHER EVENTS
  
  Termination of Negotiations to Acquire Beverly Hills Auctioneers, Inc.
  ----------------------------------------------------------------------
  On May 19, 2000, the Registrant executed a letter of intent to acquire 100% of
  the outstanding common stock of Beverly Hills Auctioneers, Inc., Beverly
  Hills, California, for newly-issued shares of capital stock of the Registrant.
  The acquisition was subject to the negotiation and completion of a definitive
  agreement setting forth the terms of the acquisition. On September 13, 2000,
  the Registrant announced that negotiations on the definitive agreement and
  broken down and no agreement had been reached between the parties.
  
  (c)  Exhibits.  The following exhibits are included as part of this report:
  
              SEC
  Exhibit     Reference
  Number      Number      Title of Document                        Location
  -------     ---------   -----------------                        --------
  20.03         20        Press Release re: Termination of
                          Letter of Intent                          This Filing
  
                              SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the Registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunder duly authorized.
  
                                           IMMUNOTECHNOLOGY CORPORATION
  
  Date: September 25, 2000                 /S/David Knudson, Secretary/Treasurer